top of page
Stay up-to-date on Laxxon's latest news + insights

In the next 10 years, 150+ drugs will come off patent protection. These drugs are worth over $100B in sales.

Our Mission

Laxxon Medical is dedicated to engineering patented 3D pharmaceutical solutions which optimize products and benefit patients.

The basis of Laxxon's pharmaceutical solutions is our cutting-edge 3D screen printing technology and the extensive intellectual property surrounding it.

Our commitment to innovation and health is fueled by the expertise, integrity, agility, and diversity of the Laxxon team.

 

Laxxon strives to accelerate pharmaceutical progress globally by establishing ourselves as the leader in the field of 3D printed drugs.

Laxxon 3D Screen Printing Technology Enables Fabrication of Oral Drug Dosage Forms with Freely Tailorable Release Profiles

Scientific Publications

banner-1-2-672023e0850eb.webp

The future of pharmaceuticals.

Engineering disruptive drug delivery solutions which optimize assets to benefit patients.

Newsroom

Laxxon Medical Announces Development Program for Non-Invasive, 3D Printed Oral GLP-1 Asset, Offering an Alternative to GLP-1 Injections on Market

Laxxon Medical Granted U.S. Patent for the Sequential Release of Multiple Drugs Within Pharmaceutical Dosage Forms

Newsroom

Pharmaceutics 3D Screen Printing Offers Unprecedented Anticounterfeiting Strategies for Oral Solid Dosage Forms Feasible for Large Scale Production

Scientific Publications

32fdab-282b5f316f9240d4802a027b2d11c976mv2-6720294c1e05f.webp

Laxxon Medical and Adare Pharma Solutions Announce Joint Cooperation for Production of cGMP 3D Printed Oral Dosage Forms in Europe and US

Newsroom

The cooperation between Laxxon and Adare enables the clinical and commercial production of advanced drug delivery systems at Adare’s cGMP facilities in Italy and US.

32fdab-4776005656af4a84a3fca9b215fa61f1mv2-6720268883409.webp

CSO Dr. Achim Schneeberger Discusses LXM.5, New Generation Levodopa/Carbidopa Parkinson’s Treatment

Newsroom

32fdab-69c2a56199e44366b7a78cd338aa0b6dmv2-6720274fa8a75.webp

Laxxon Medical to Showcase LXM.2, Innovative Oral GLP-1 Agonist including Multi-Compartment Micro-Tablet Form at 2024 BIO-Europe Convention

Newsroom

Laxxon is seeking out-licensing opportunities for our lead asset LXM.2, an innovative, customizable, oral GLP-1 Agonist tablet. 

Presentation

Pioneering Better, Smarter Medicine: Webinar Presentation with CEO Helmut Kerschbaumer 

November 14, 2024 – CEO Helmut Kerschbaumer walks through Laxxon's patented oral drug delivery platform technology & pipeline. 

32fdab-4776005656af4a84a3fca9b215fa61f1mv2-6720268883409.webp

Laxxon Medical Names Lauren Chung PhD MBA as Chief Financial Officer

Newsroom

c647fc-59e65473fc944b9a8b40e77f96d69e1fmv2-67202aaa90eb5.webp

Laxxon is dedicated to revolutionizing the pharmaceutical industry with better, smarter drug delivery solutions for patients. 

Laxxon is global leader of smart drug delivery systems in the pharmaceutical industry, pioneering a new generation of advanced oral drug delivery forms with SPID®, our additive manufacturing technology platform.

 

For new and common pharmaceutical drugs, SPID® unlocks innovative drug delivery advancements paired with fast-tracked market access and extensive IP protection to yield disruptive opportunities in the pharmaceutical space. 

Our Commercial Solutions for Pharma

 

The future of pharmaceuticals.

Engineering disruptive drug delivery solutions which optimize assets to benefit patients.

IMG_0261 copy_edited.jpg

In the next 10 years, 150+ drugs will come off patent protection. These drugs are worth over $100 Billion in sales.

Events

Laxxon has both an external pipeline and in-house Advanced Patented Generic pipeline.

03.

Pipeline consists of 13 in-house products and 3 products that are being developed for external clients

All products created with our SPID®-Technology manufacturing approach are patent protected, 

whether engineered in-house or with an external partner

bottom of page